METHYS Dx is a company dedicated to the development of personalized medicine through non-invasive monitoring techniques. Among these, liquid biopsies, i.e. the analysis of biological fluids (e.g. blood, urine, etc.), allow, among other things, the detection of specific cancer markers.
The objective of METHYS Dx is thus to provide innovative solutions for the characterization of molecules released by tumor cells in biological effluents. Our innovations will allow researchers to better understand the evolution of the disease, doctors to follow their patients and biologists to have robust techniques that are sensitive and easy to implement. Among the molecules released by tumor cells, METHYS Dx is particularly interested in cell-free circulating tumor DNA and is committed to develop efficient technics for its characterization.
Who are we ?
Based in Paris, METHYS Dx was created by a team of internationally recognized experts, both from a clinical and technological point of view. These expert comes from two teams: the MEPPOT team (Médecine Personnalisée, Pharmacogénomiques et Optimisations Thérapeutiques, Centre de recherche des Cordeliers, Université Paris Cité), recognized for his work in the field of oncology, liquid biopsy, cancer biomarkers and digital PCR, and the SPM group (Systèmes et programmes moléculaires, laboratoire Gulliver, ESPCI, PSL), specialized in molecular programming and DNA detection technologies.
The synergy of these skills and knowledge thus enables METHYS Dx to develop highly innovative diagnostic tools for monitoring cancer patients.